Reductions in Human Papillomavirus-Disease Resource Use and Costs with Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccination: The FUTURE Study Economic Evaluation
Ralph P. Insinga, Erik J. Dasbach, Shannon E. Allen, George W. Carides, Evan R. MyersVolume:
11
Year:
2008
Language:
english
Pages:
11
DOI:
10.1111/j.1524-4733.2008.00342.x
File:
PDF, 123 KB
english, 2008